<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0111222862
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAMIFEN 250MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERBINAFINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D01BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Terbinafine, the active ingredient in Lamifen&trade; Tablets, is an antifungal medicine.<br />Lamifen&trade; Tablets are used to treat a number of fungal infections of the skin and nails.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Some people MUST NOT take Lamifen&trade; Tablets. Talk to your doctor if:<br />&bull; you think you may be allergic to terbinafine or to any of the other ingredients of<br />Lamifen&trade; Tablets. (These are listed in Section 6).<br />&bull; you have or have had any liver problems.<br />&bull; you are breast-feeding.<br />You should also ask yourself these questions before taking Lamifen&trade; Tablets. If the<br />answer to any of these questions is YES, tell your doctor or pharmacist because Lamifen&trade;<br />Tablets might not be the right medicine for you.<br />&bull; Are you pregnant or trying to become pregnant?<br />&bull; Do you have any problems with your kidneys or liver?<br />&bull; Do you have psoriasis?<br />&bull; Do you have systemic lupus erythematosis (SLE)?<br />&bull; Do you have rash due toa high level of a specific type of white blood cells?<br />Children should not normally be given Lamifen&trade; tablets.<br />Are you taking other medicines?<br />Some medicines can interfere with your treatment. Tell your doctor if you are taking any of<br />the following:<br />&bull; Rifampicin for infections<br />&bull; Cimetidine for gastric problems such as indigestion or ulcer<br />&bull; Antidepressants including tricyclic antidepressants, SSRIs (selective serotonin reuptake<br />inhibitors), or MAOIs (monoamine oxidase inhibitors)<br />&bull; Oral contraceptives (as irregular periods and breakthrough bleeding may occur in some<br />female patients)<br />&bull; Beta-blockers or anti-arrhythmics for heart problems<br />&bull; Warfarin, a medicine used to thin your blood<br />&bull; Medicines to treat heart problems (eg propafenone, amiodarone)<br />&bull; Ciclosporin, a medicine used to control your body&rsquo;s immune system in order to prevent<br />rejection of transplanted organs<br />&bull; Medicines used to treat fungal infections (eg fluconazole, ketoconazole)<br />&bull; Medicines used to treat cough (eg dextromethorphan)<br />&bull; Caffeine<br />Always tell your doctor about all the medicines you are taking. This means medicines you<br />have bought yourself as well as medicines on prescription from your doctor.<br />You should have blood tests before and during treatment with Lamifen&trade; Tablets to<br />monitor your liver function.</p><p>Will there be any problems with driving or using machinery?<br />Some people have reported feeling dizzy or giddy while they are taking Lamifen&trade;<br />Tablets. If you feel like this you should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will decide what dose of Lamifen&trade; Tablets you should take. Always take the<br />tablets exactly as your doctor has told you to. The dose will be on the pharmacist&rsquo;s label.<br />Check the label carefully. It should tell you how many tablets to take, and how often. If<br />you are not sure, ask your doctor or pharmacist. Keep taking the tablets for as long as you<br />have been told unless you have any problems. In that case, check with your doctor.<br />The usual dose for adults, including the elderly, is 250 mg once a day.<br />&bull; For skin infections continue taking the tablets for 2 to 6 weeks.<br />&bull; For nail infections treatment usually lasts for between 6 weeks and 3 months, although<br />some patients with toenail infections may need to be treated for 6 months or longer.<br />&bull; If your kidneys are not working very well, your doctor may reduce the dose of Lamifen&trade;<br />Tablets you take.<br />&bull; Swallow the tablets whole with a glass of water.<br />What if you forget to take a dose?<br />If you miss taking a Lamifen&trade; Tablet, do not worry. Take it as soon as you remember.<br />Take your next tablet at the usual time, then carry on as normal until you have finished all<br />the tablets. It is important that you finish all the tablets you have been given unless your<br />doctor tells you to stop taking them.<br />What if you take too many tablets?<br />All tablets can be risky if you take too many. If you take too many Lamifen&trade; Tablets at<br />once, tell your doctor or hospital casualty department as soon as possible. Take your<br />medicine pack with you so that people can see what you have taken.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lamifen&trade; Tablets are suitable for most people, but, like all medicines, they can<br />sometimes cause side effects. Any side effects are usually mild or moderate and don&rsquo;t last<br />for too long.<br />Some side effects can be serious<br />Stop taking the tablets and tell your doctor immediately if you notice any of the<br />following rare symptoms:<br />&bull; Yellowing of your skin or eyes. Unusually dark urine or pale faeces, unexplained<br />persistent nausea, stomach problems, loss of appetite or unusual tiredness or weakness (this<br />may indicate liver problems), increase in liver enzymes which may be noted on a blood test<br />result.<br />&bull; Severe skin reactions including rash, light sensitivity, blistering or wheals.<br />&bull; Weakness, unusual bleeding, bruising, abnormal pale skin, unusual tiredness, or<br />weakness or breathlessness on exertion or frequent infections (this may be a sign of blood<br />disorders)</p><p>&bull; Difficulty breathing, dizziness, swelling mainly of the face and throat, flushing, crampy<br />abdominal pain, stiffness, rash, fever or swollen/enlarged lymph nodes (possible signs of<br />severe allergic reactions)<br />&bull; Symptoms such as rash, fever, itching, tiredness or if you notice appearance of purplish<br />spots under the skin surface (signs of blood vessel inflammation)<br />&bull; Severe upper stomach pain which spreads to the back (possible signs of pancreas<br />inflammation)<br />&bull; Unexplained muscle weakness or pain, or dark (red-brown) urine (possible signs of muscle<br />breakdown)<br />The most common side effects are:-<br />&bull; Headache<br />&bull; Stomach problems such as loss of appetite, ache, indigestion, feeling bloated or sick<br />&bull; Diarrhoea &bull; Itching, rash or swelling &bull; Pains in the muscles and joints<br />The side effects listed below have also been reported.<br />Up to 1 in 100 people have experienced:<br />Taste loss and taste disturbance. This usually disappears within several weeks after you stop<br />taking the medicine. However, a very small number of people, (less than 1 in 10,000), have<br />reported that the taste disturbance lasts for some time and, as a result, they go off their food<br />and lose weight. There have also been reports of some people experiencing anxiety or<br />symptoms of depression as a result of these taste disturbances.<br />Up to 1 in 1,000 people have experienced:<br />&bull; Feeling unwell, dizzy &bull; Numbness or tingling<br />Up to 1 in 10,000 people have experienced:<br />&bull; Feeling tired<br />&bull; Decrease in the number of some blood cells. You may notice that you seem to bleed<br />or bruise more easily than normal, or you may catch infections easily and these might<br />be more severe than usual.<br />&bull; Psoriasis like skin eruptions, or worsening of any psoriasis including a rash or eruption of<br />small pus containing blisters.<br />&bull; Vertigo &bull; Hair loss<br />&bull; Onset or worsening of a condition called lupus (a long-term illness with symptoms<br />including skin rash and pain in the muscles and joints)<br />The following have also been reported:<br />Signs of blood disorders: weakness, unusual bleeding, bruising or frequent infections.<br />Disorders of sense of smell which may be permanent, impaired hearing, hissing and/or<br />ringing in the ears, flu like symptoms, increase in blood of a muscle enzyme called creatine<br />phosphokinase (may be found on a blood test).<br />If any of the symptoms become troublesome, or if you notice anything else not<br />mentioned here, please go and see your doctor. He/she may want to give you a different<br />medicine.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side<br />effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store the tablets in their original pack away from direct light. Do not store above 30 &ordm;C. Do<br />not take the tablets after their expiry date which is printed on the outside of the pack. If your<br />doctor tells you to stop taking Lamifen&trade; Tablets, please take any unused tablets back to your<br />pharmacist to be destroyed. Only keep the tablets if the doctor tells you to. Do not throw<br />them away with your normal household water or waste. This will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>And they contain 250 mg of the active ingredient terbinafine. They also contain the inactive<br />ingredients : microcryastalline cellulose, maize starch, sodium starch glycolate, hydroxy<br />propyl methylcellulose, colloidal silicone dioxide, magnesium stearate.<br />They come in blister packs of 7 or 14 tablets.<br />Not all pack sizes are may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lamifen™ Tablets are round, white to off white tablets , plain on one side and on the other
side breaking line with engrave 'JP 24'.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111. Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><br /><br />&nbsp;تربينافين، المادة الفعالة في لامفين أقراص، وهى دواء مضاد للفطريات.<br />يستخدم لامفين أقراص لعلاج عدد من الالتهابات الفطرية في الجلد والأظافر.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أقراص. تحدث إلى طبيبك إذا: TM بعض الناس يجب أن لا يتناولوا لامفين<br />أقراص. TM &bull; كنت تعتقد أن لديك حساسية من تربينافين أو إلى أي من المكونات الأخرى لامفين<br />(. (يتم سرد هذه في القسم ٦<br />&bull; كنت تقومين بالرضاعة الطبيعية.<br />أقراص TM يجب عليك أن تسأل نفسك هذه الأسئلة أيضا قبل أخذ لامفين<br />أقراص هو الدواء TM إذا كانت الإجابة على أي من هذه الأسئلة هو نعم، أخبر طبيبك أو الصيدلي فقد لا يكون لامفين<br />المناسب لك.<br />&bull; هل أنت حامل أو تحاولين ان تصبحين حاملا؟<br />&bull; هل لديك أي مشاكل مع الكليتين أو الكبد؟<br />&bull; هل لديك صدفية ؟<br />أقراص إلا عند الضرورة. TM لا ينبغي أن يعطى الأطفال عادة لامفين<br />هل تتناول أدوية أخرى؟<br />يمكن لبعض الأدوية أن تتداخل مع علاجك. أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية:<br />&bull; ريفامبيسين للعدوى.<br />&bull; سيميتيدين لمشاكل المعدة مثل عسر الهضم أو قرحة.<br />&bull; مضادات الاكتئاب بما في ذلك مضادات الاكتئاب ثلاثية الحلقات، مثبطات امتصاص السيروتونين الانتقائية ، أو<br />مثبطات أوكسيديز أحادي الأمين.<br />&bull; حبوب منع الحمل (قد يحدث عدم انتظام الدورة ونزيف مفاجئ في بعض المرضى من النساء).<br />&bull; حاصرات بيتا أو مضادات اضطراب النظم لمشاكل القلب.<br />&bull; الوارفارين، وهو دواء يستخدم لترقيق الدم .<br />&bull; أدوية لعلاج مشاكل القلب (مثل بروبافينون ، اميودارون).<br />&bull; سيكلوسبورين، وهو دواء يستخدم للتحكم في نظام مناعة الجسم من أجل منع رفض الجسم للأعضاء المزروعة.<br />&bull; أدوية مستخدمة لعلاج الالتهابات الفطرية (مثل فلوكونازول، الكيتوكونازول).<br />&bull; أدوية مستخدمة لعلاج السعال (مثل ديكستروميتورفان).<br />&bull; الكافيين<br />اخبر طبيبك دائماً حول جميع الأدوية التي تتناولها . سواء كانت أدوية اشتريتها من نفسك أو أدوية بناء على وصفة من<br />طبيبك.<br />هل سيكون هناك أي مشاكل مع القيادة او استخدام الآلات؟<br />أقراص. إذا كنت تشعر بمثل هذا يجب أن لا TM بعض الناس افادوا بشعورهم بالدوار أو الدوخة بينما هم يتناولون لامفين<br />تقود أو تشغل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />أقراص التي يجب أن تتناولها . دائما تناول الأقراص تماما كما قد قال لك طبيبك. TM سوف يقرر الطبيب جرعة لامفين<br />سوف تكون الجرعة على ملصق الصيدلي. تحقق من الملصق بعناية. ينبغي أن يخبرك كم قرص تتناول و عدد المرات.<br />إذا لم تكن متأكدا، استشر طبيبك أو الصيدلي. حافظ على تناول الأقراص كما قيل لك إلا إذا كان لديك أي مشاكل. في<br />هذه الحالة، راجع طبيبك.<br />الجرعة المعتادة للبالغين، بما في ذلك كبار السن، هي قرص واحد ۲٥۰ ملجم مرة واحدة يوميا.<br />&bull; لعدوى الجلد استمر في تناول الأقراص لمدة من ۲ إلى ٦ أسابيع.<br />&bull; بالنسبة لعدوى الأظافر العلاج يستمر عادة لمدة تتراوح بين ٦ أسابيع إلى ۳ أشهر، رغم أن بعض المرضى الذين<br />يعانون من عدوى أظافر القدم قد يحتاجوا إلى أن العلاج لمدة ٦ أشهر أو أكثر.<br />&bull; إذا كانت الكليتين لا تعمل بشكل جيد للغاية، قد يقلل الطبيب من جرعة<br />أقراص التي تأخذها. TM لامفين<br />&bull; ابلع الأقراص كاملة مع كوب من الماء.<br />الأطفال:<br />أقراص للأطفال أقل من عامين ( غالباً أقل من ۱۲ كلجم). TM لا توجد معلومات متوفرة عن إستعمال لامفين<br />الأطفال أقل من وزن ۲۰ كلجم تكون الجرعة ٦۲,٥ ملجم (ربع حبة) مرة واحدة يوميا.<br />الأطفال وزن ۲۰ إلي ٤۰ كلجم ۱۲٥ ملجم (نصف حبة) مرة واحدة يوميا.<br />الأطفال وزن ٤۰ كلجم فما فوق ۲٥۰ ملجم (حبة واحدة ) مرة واحدة يوميا .<br />ماذا لو نسيت أن تتناول الجرعة ؟<br />أقراص، لا تقلق. وتناولها فور أن تتذكر. تناول القرص التالي في الوقت المعتاد، TM إذا نسيت أن تتناول جرعة لامفين<br />ثم استمر كالمعتاد حتى الانتهاء من جميع الأقراص. من المهم الانتهاء من جميع الأقراص التي أعطيت لك ما لم يخبرك<br />طبيبك التوقف عن تناولها.<br />ماذا لو تناولت الكثير من الأقراص ؟<br />أقراص في وقت TM جميع الأقراص يمكن أن تكون خطرة إذا تناولت الكثير جدا منها. إذا تناولت الكثير من لامفين<br />واحد، أخبر طبيبك أو المستشفى قسم الحوادث في أقرب وقت ممكن. خذ علبة الدواء الخاصة بك معك حتى يتمكن<br />الناس من معرفة ما تناولت.</p><p><br />أقراص التي يجب أن تتناولها . دائما تناول الأقراص تماما كما قد قال لك طبيبك. TM سوف يقرر الطبيب جرعة لامفين<br />سوف تكون الجرعة على ملصق الصيدلي. تحقق من الملصق بعناية. ينبغي أن يخبرك كم قرص تتناول و عدد المرات.<br />إذا لم تكن متأكدا، استشر طبيبك أو الصيدلي. حافظ على تناول الأقراص كما قيل لك إلا إذا كان لديك أي مشاكل. في<br />هذه الحالة، راجع طبيبك.<br />الجرعة المعتادة للبالغين، بما في ذلك كبار السن، هي قرص واحد ۲٥۰ ملجم مرة واحدة يوميا.<br />&bull; لعدوى الجلد استمر في تناول الأقراص لمدة من ۲ إلى ٦ أسابيع.<br />&bull; بالنسبة لعدوى الأظافر العلاج يستمر عادة لمدة تتراوح بين ٦ أسابيع إلى ۳ أشهر، رغم أن بعض المرضى الذين<br />يعانون من عدوى أظافر القدم قد يحتاجوا إلى أن العلاج لمدة ٦ أشهر أو أكثر.<br />&bull; إذا كانت الكليتين لا تعمل بشكل جيد للغاية، قد يقلل الطبيب من جرعة<br />أقراص التي تأخذها. TM لامفين<br />&bull; ابلع الأقراص كاملة مع كوب من الماء.<br />الأطفال:<br />أقراص للأطفال أقل من عامين ( غالباً أقل من ۱۲ كلجم). TM لا توجد معلومات متوفرة عن إستعمال لامفين<br />الأطفال أقل من وزن ۲۰ كلجم تكون الجرعة ٦۲,٥ ملجم (ربع حبة) مرة واحدة يوميا.<br />الأطفال وزن ۲۰ إلي ٤۰ كلجم ۱۲٥ ملجم (نصف حبة) مرة واحدة يوميا.<br />الأطفال وزن ٤۰ كلجم فما فوق ۲٥۰ ملجم (حبة واحدة ) مرة واحدة يوميا .<br />ماذا لو نسيت أن تتناول الجرعة ؟<br />أقراص، لا تقلق. وتناولها فور أن تتذكر. تناول القرص التالي في الوقت المعتاد، TM إذا نسيت أن تتناول جرعة لامفين<br />ثم استمر كالمعتاد حتى الانتهاء من جميع الأقراص. من المهم الانتهاء من جميع الأقراص التي أعطيت لك ما لم يخبرك<br />طبيبك التوقف عن تناولها.<br />ماذا لو تناولت الكثير من الأقراص ؟<br />أقراص في وقت TM جميع الأقراص يمكن أن تكون خطرة إذا تناولت الكثير جدا منها. إذا تناولت الكثير من لامفين<br />واحد، أخبر طبيبك أو المستشفى قسم الحوادث في أقرب وقت ممكن. خذ علبة الدواء الخاصة بك معك حتى يتمكن<br />الناس من معرفة ما تناولت.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><br />أقراص مناسبة لمعظم الناس، ولكن، مثل كل الأدوية، يمكن أن تسبب أحيانا أعراض جانبية. أي آثار جانبية TM لامفين<br />عادة ما تكون خفيفة أو متوسطة ولا تستمر لفترة طويلة .<br />بعض الآثار الجانبية يمكن أن تكون خطيرة<br />توقف عن تناول الأقراص وأخبر طبيبك فورا إذا لاحظت أي من الأعراض النادرة التالية:<br />&bull; اصفرار الجلد أو العينين. بول داكن غير عادي أو براز شاحبا ، غثيان مستمر غير مبرر، مشاكل في المعدة، فقدان<br />الشهية أو التعب أوضعف غيرعادي (هذا قد يدل على مشاكل في الكبد).<br />&bull; ردود فعل جلدية شديدة بما في ذلك الطفح الجلدي، الحساسية للضوء، أو ظهور تقرحات شروية.<br />&bull; ضعف ونزيف غير عادي، كدمات ، جلد شاحب غير طبيعي، إرهاق غير عادي، ضعف أو ضيق التنفس مع الجهد<br />أو عدوي متكررة (وهذا قد يكون علامة على اضطرابات الدم)</p><p>&bull; صعوبة في التنفس، دوخة، تورم بشكل رئيسي في الوجه والحلق، بيغ، ألم في البطن ، تيبس ، طفح جلدي، حمى أو<br />تضخم الغدد الليمفاوية (علامات ممكنة لتفاعلات الحساسية الشديدة)<br />&bull; أعراض مثل الطفح والحمى، الحكة ، و التعب أو إذا لاحظت ظهور بقع أرجوانية تحت سطح الجلد (علامات لإلتهاب<br />الأوعية الدموية)<br />&bull; آلام شديدة في الجزئ العلوى من المعدة تنتشر إلى الظهر (علامات ممكنة لإلتهاب البنكرياس )<br />&bull; ضعف العضلات غير المبرر أو آلام ، أو بول قاتم (أحمر والبني) (علامات ممكنة لانهيار العضلات).<br />الآثار الجانبية الأكثر شيوعا هي: -<br />&bull; الصداع<br />&bull; مشاكل المعدة مثل فقدان الشهية، آلام وعسر الهضم، والشعور بالإمتلاء أو المرض .<br />&bull; الإسهال<br />&bull; الحكة والطفح الجلدي أو تورم.<br />&bull; آلام في العضلات والمفاصل.<br />الأعراض الجانبية التالية تم رصدها:<br />رصدت في ۱ من ۱۰۰ شخص :<br />فقدان التذوق واضطراب التذوق. وهذا يختفي عادة عند التوقف عن تناول الدواء. ومع ذلك، فقد أفاد عدد قليل جدا من<br />الناس، (أقل من ۱ في ۱۰,۰۰۰ )، أن اضطراب التذوق إستمر لبعض الوقت، ونتيجة لذلك، فإنهم يتركون طعامهم<br />ويفقدون وزن. كانت هناك أيضا تقارير عن بعض الناس الذين يعانون من القلق أو أعراض الاكتئاب نتيجة<br />لاضطرابات التذوق هذه.<br />رصدت في ۱ من ۱,۰۰۰ شخص :<br />&bull; شعوره بالتوعك والدوار<br />&bull; خدر أو وخز<br />رصدت في ۱ من ۱۰,۰۰۰ شخص:<br />&bull; الشعور بالتعب<br />&bull; انخفاض في عدد بعض خلايا الدم . قد تلاحظ أنك يحدث لك نزيف أو كدمة بسهولة أكبر من المعتاد، أو قد يحدث لك<br />عدوى بسهولة، وهذه قد تكون أكثر حدة من المعتاد.<br />&bull; الصدفية مثل الطفح الجلدى، أو تفاقم مرض الصدفية<br />&bull; الدوار<br />&bull; بداية أو تفاقم حالة الذئبة (مرض طويل الأمد مع أعراض تشمل الطفح الجلدي وآلام في العضلات والمفاصل)<br />وقد تم رصد الاتي : الصدفية مثل الطفح الجلدي، أو تفاقم مرض الصدفية، ردود فعل جلدية شديدة بما في ذلك طفح<br />جلدي أو طفح قيح صغيرة تحتوي على بثور. علامات اضطرابات الدم: ضعف، نزيف غير عادي، كدمات أو التهابات<br />متكررة .<br />اضطرابات حاسة الشم التي قد تكون دائمة، ضعف السمع، الهسهسة و / أو طنين في الأذنين، أعراض تشبه الانفلونزا،<br />وزيادة في الدم من انزيم العضلات يسمى انزيم الكرياتين فسفوكيناز (يمكن ان يوجد في فحص الدم) .<br />إذا كان أي من أعراض مزعجة، أو إذا لاحظت أي أعراض آخري غير مذكورة هنا، يرجى الذهاب واستشارة الطبيب.<br />فقد يريد أن يعطيكم دواء مختلف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ الأقراص في عبوتها الأصلية بعيدا عن الضوء المباشر. يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />TM لا تستعمل الأقراص بعد تاريخ انتهاء صلاحيتها المطبوع على العلبة. إذا طلب منك الطبيب التوقف عن تناول لامفين<br />أقراص، يرجى أخذ أي أقراص غير مستخدمة إلى الصيدلي ليتم تدميرها. ابقي علي الأقراص فقط إذا اخبرك الطبيب<br />هذا. لا ترمي بها بعيدا مع المياه المنزلية العادية أو النفايات. فهذا سوف يساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أقراص هي أقراص مستديرة لونها أبيض إلى أبيض فاتح ، عادية من جانب ومن الجانب الآخر محززة مع TM لامفين<br />ويحتوي كل قرص على ۲٥۰ ملجم من المادة الفعالة تربينافين. كما أنها تحتوي على مكونات غير ،.&#39;JP نقش &#39; 24<br />فعالة : ميكروكريستالين سيليلوز، نشا الذرة، جليكولات نشا الصوديوم، هيدروكسي بروبيل ميثيل سليلوز، ثاني أكسيد<br />السيليكون الغروية ، ستيرات المغنيسيوم.<br />متوفرة في عبوات ۷ أقراص أو ۱٤ قرص.<br />قد تكون بعض احجام العبوات غير مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص هي أقراص مستديرة لونها أبيض إلى أبيض فاتح ، عادية من جانب ومن الجانب الآخر محززة مع TM لامفين<br />ويحتوي كل قرص على ۲٥۰ ملجم من المادة الفعالة تربينافين. كما أنها تحتوي على مكونات غير ،.&#39;JP نقش &#39; 24<br />فعالة : ميكروكريستالين سيليلوز، نشا الذرة، جليكولات نشا الصوديوم، هيدروكسي بروبيل ميثيل سليلوز، ثاني أكسيد<br />السيليكون الغروية ، ستيرات المغنيسيوم.<br />متوفرة في عبوات ۷ أقراص أو ۱٤ قرص.<br />قد تكون بعض احجام العبوات غير مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">شركة مصنع جمجوم للأدویة،<br />جدة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+966-11-205-7662 فاكس: o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o</p><p dir="ltr">+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o</p><p dir="ltr">تحويلة: 2340-2356-2317</p><p dir="ltr">الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p><p dir="ltr">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 281.35mg terbinafine hydrochloride, equivalent to 250mg terbinafine.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 281.35mg terbinafine hydrochloride, equivalent to 250mg terbinafine.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets for oral administration. White to off white, round, about 11 mm in diameter, biconvex uncoated tablets with beveled edges, plain on one side and on the other side breaking with engrave 'JP 24'
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fungal infections of the skin and nails caused by Trichophyton (eg. T. rubrum, T.mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum. 1. Oral Terbinafine is indicated in the treatment of ringworm (tinea corporis, tinea cruris and tinea pedis) where oral therapy is considered appropriate due to the site, severity or extent of the infection. 2. Oral Terbinafine is indicated in the treatment of onychomycosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;</p><p><u>Adults</u></p><p>250mg once daily.</p><p>The duration of treatment varies according to the indication and the severity of the infection.</p><p><em><u>Skin infections</u></em></p><p>Likely durations of treatment are as follows:</p><table cellspacing="0" cellpadding="0" border="0" style="width:518.25pt"><tbody><tr><td><p>Tinea pedis (interdigital, plantar/moccasin type):</p></td><td><p>2 to 6 weeks</p></td></tr><tr><td><p>Tinea corporis:</p></td><td><p>4 weeks</p></td></tr><tr><td><p>Tinea cruris:</p></td><td><p>2 to 4 weeks</p></td></tr></tbody></table><p><em><u>Onychomycosis</u></em></p><p>The duration of treatment for most patients is between 6 weeks and 3 months. Treatment periods of less than 3 months can be anticipated in patients with fingernail infection, toenail infection other than of the big toe, or patients of younger age. In the treatment of toenail infections, 3 months is usually sufficient although a few patients may require treatment of 6 months or longer. Poor nail outgrowth during the first weeks of treatment may enable identification of those patients in whom longer therapy is required.</p><p>Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.</p><p><u>Additional information on special population</u></p><p><em><u>Liver impairment</u></em></p><p>Lamifen tablets are contraindicated for patients with chronic or active hepatic disease (see sections 4.3 Contraindications and 4.4 Special warnings and precautions for use).</p><p><em><u>Renal impairment</u></em></p><p>The use of Lamifen tablets has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section 4.4 Special warnings and precautions for use and section 5.2 Pharmacokinetic properties).</p><p><u>Children</u></p><p>A review of safety experience with oral LAMIFEN in children, which includes 314 patients involved in the UK LAMIFEN Post Marketing Surveillance study, has shown that the adverse event profile in children is similar to that seen in adults. No evidence of any new, unusual or more severe reactions to those seen in the adult population have been noted. However, as data is still limited its use is not recommended.</p><p><u>Elderly</u></p><p>There is no evidence to suggest that elderly patients (aged 65 years or above) require different dosages or experience side-effects different to those of younger patients. The possibility of impairment of liver or kidney function should be considered in this age group (see Precautions).</p><p><u>Method of administration</u></p><p>The scored tablets are taken orally with water. They should preferably be taken at the same time each day and can be taken on an empty stomach or after a meal.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to terbinafine or to any of the excipients of Lamifen tablets.

Chronic or active hepatic disease.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Liver Function Terbinafine tablets are contraindicated for patients with chronic or active hepatic disease. Before prescribing Terbinafine tablets, a liver function test should be performed and any pre-existing liver disease should be assessed. Hepatotoxicity may occur in patients with and without pre-existing liver disease therefore periodic monitoring (after 4-6 weeks of treatment) of liver function test is recommended. Terbinafine tablets should be immediately discontinued in case of elevation of liver function test. Very rare cases of serious liver failure (some with a fatal outcome, or requiring liver transplant) have been reported in patients treated with Terbinafine tablets. In the majority of liver failure cases the patients had serious underlying systemic conditions. Patients prescribed Terbinafine tablets should be instructed to report immediately any signs or symptoms suggestive of liver dysfunction such as pruritus, unexplained persistent nausea, decreased appetite, anorexia, jaundice, vomiting, fatigue, right upper abdominal pain, dark urine, or pale stools. Patients with these symptoms should discontinue taking oral terbinafine and the patient&#39;s liver function should be immediately evaluated. Dermatological effects Serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms) have been very rarely reported in patients taking Terbinafine tablets. If progressive skin rash occurs, Terbinafine tablets treatment should be discontinued. Terbinafine should be used with caution in patients with pre-existing psoriasis, as very rare cases of exacerbation of psoriasis have been reported. Haematological effects Very rare cases of blood dyscrasias (neutropenia, agranulocytosis, thrombocytopenia, pancytopenia) have been reported in patients treated with Terbinafine tablets. Aetiology of any blood dyscrasias that occur in patients treated with Terbinafine tablets should be evaluated and consideration should be given for a possible change in medication regimen, including discontinuation of treatment with Terbinafine tablets.</p><p>Renal function In patients with renal impairment (creatinine clearance less than 50 mL/min or serum creatinine of more than 300 micro mol/L) the use of Terbinafine tablets has not been adequately studied, and therefore, is not recommended. Other Terbinafine should be used with caution in patients with lupus erythematosus as very rare cases of lupus erythematosus have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of other medicinal products on terbinafine The plasma clearance of terbinafine may be accelerated by drugs which induce metabolism and may be inhibited by drugs which inhibit cytochrome P450. Where co-administration of such agents is necessary, the dosage of Terbinafine may need to be adjusted accordingly. The following medicinal products may increase the effect or plasma concentration of terbinafine: Cimetidine decreased the clearance of terbinafine by 30%. Fluconazole increased the Cmax and AUC of terbinafine by 52% and 69% respectively, due to inhibition of both CYP2C9 and CYP3A4 enzymes. Similar increase in exposure may occur when other drugs which inhibit both CYP2C9 and CYP3A4 such as ketoconazole and amiodarone are concomitantly administered with terbinafine. The following medicinal products may decrease the effect or plasma concentration of terbinafine: Rifampicin increased the clearance of terbinafine by 100%. Effect of terbinafine on other medicinal products Terbinafine may increase the effect or plasma concentration of the following medicinal products: Caffeine &ndash; Terbinafine decreased the clearance of caffeine administered intravenously by 21%. Compounds predominantly metabolised by CYP2D6 &ndash; In vitro and in vivo studies have shown that terbinafine inhibits the CYP2D6-mediated metabolism. This finding may be of clinical relevance for patients receiving compounds predominantly metabolised by CYP2D6, e.g. certain members of the following drug classes, tricyclic antidepressants (TCA&#39;s), &beta;-blockers, selective serotonin reuptake inhibitors (SSRIs), antiarrhythmics (including class 1A, 1B and 1C) and monoamine oxidase inhibitors (MAO-Is) Type B, especially if they also have a narrow therapeutic window (see section 4.4). Terbinafine decreased the clearance of desipramine by 82%.</p><p>In studies in healthy subjects characterized as extensive metabolisers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increased the dextromethorphan/dextrorphan metabolic ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolisers (genotype) to poor metaboliser status (phenotype). Information on other drug concomitantly used with Terbinafine resulting in no or negligible interactions. Studies undertaken in vitro and in healthy volunteers suggest that terbinafine shows negligible potential to inhibit or induce the clearance of most drugs that are metabolized via other cytochrome P450 enzymes (e.g. tolbutamine, terfenadine, triazolam, oral contraceptives) with exception of those metabolised through CYP2D6 (see below). Terbinafine does not interfere with the clearance of antipyrine or digoxin. There was no effect of terbinafine on the pharmacokinetics of fluconazole. Further there was no clinically relevant interaction between terbinafine and the potential comedications cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline. Some cases of menstrual disturbance (breakthrough bleeding and irregular cycle) have been reported in patients taking Terbinafine concomitantly with oral contraceptives, although the incidence of these disorders remains within the background incidence of patients taking oral contraceptives alone. Terbinafine may decrease the effect or plasma concentration of the following medicinal products: Terbinafine increased the clearance of ciclosporin by 15%. Rare cases of changes in INR and/or prothrombin time have been reported in patients receiving terbinafine concomitantly with warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Foetal toxicity and fertility studies in animals suggest no adverse effects. Since clinical experience in pregnant women is very limited, terbinafine tablets should not be used during pregnancy unless clinical condition of the woman requires treatment with oral terbinafine and the potential benefits for the mother outweigh any potential risks for the foetus.</p><p>Lactation Terbinafine is excreted in breast milk and therefore mothers should not receive Terbinafine treatment whilst breast-feeding. Fertility Foetal toxicity and fertility studies in animals suggest no adverse effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Terbinafine tablets treatment on the ability to drive and use machines have been performed. Patients who experience dizziness as an undesirable effect should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects are generally mild to moderate, and transient. The following adverse reactions have been observed in the clinical trials or during post-marketing experience.</p><p>Adverse reactions are ranked under headings of frequency, using the following convention:</p><p>Very common (&ge; 1/10); Common (&ge; 1/100, &lt; 1/10); Uncommon (&ge; 1/1,000, &lt;1/100); Rare (&ge; 1/10,000, &lt; 1/1,000); Very rare (&lt; 1/10,000), Not known (frequency cannot be estimated from available data).</p><table cellspacing="0" cellpadding="0" border="1" style="width:518.25pt"><tbody><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="border-color:#7b7b7b; vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very rare</p></td><td style="vertical-align:top; width:61.0%"><p>Neutropenia, agranulocytosis, thrombocytopenia</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Anaemia, pancytopenia</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very rare</p></td><td style="vertical-align:top; width:61.0%"><p>Anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Anaphylactic reaction, serum sickness-like reaction</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very common</p></td><td style="vertical-align:top; width:61.0%"><p>Decreased appetite</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Anxiety and depressive symptoms</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Common</p></td><td style="vertical-align:top; width:61.0%"><p>Headache</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Uncommon</p></td><td style="vertical-align:top; width:61.0%"><p>Dysgeusia* including ageusia*</p><p><strong>*</strong>&nbsp;Hypogeusia, including ageusia, which usually recover within several weeks after discontinuation of the drug. Isolated cases of prolonged hypogeusia have been reported.</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Rare</p></td><td style="vertical-align:top; width:61.0%"><p>Paraesthesia, hypoaesthesia, dizziness</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Anosmia including permanent anosmia, hyposmia</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Visual impairment, vision blurred, visual acuity reduced</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very rare</p></td><td style="vertical-align:top; width:61.0%"><p>Vertigo</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Hypoacusis, impaired hearing, tinnitus</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Vasculitis</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very common</p></td><td style="vertical-align:top; width:61.0%"><p>Gastrointestinal symptoms (feeling of fullness abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea)</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Pancreatitis</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Rare</p></td><td style="vertical-align:top; width:61.0%"><p>Cases of serious hepatic dysfunction, including hepatic failure, hepatic enzymes increased, jaundice, cholestasis and hepatitis. If hepatic dysfunction develops, treatment with Lamifen should be discontinued (see also Section 4.4). Very rare cases of serious liver failure have been reported (some with a fatal outcome, or requiring liver transplant). In the majority of liver failure cases the patients had serious underlying systemic conditions and a causal association with the intake of Lamifen was uncertain.</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very common</p></td><td style="vertical-align:top; width:61.0%"><p>Rash, urticaria</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very rare</p></td><td style="vertical-align:top; width:61.0%"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis), erythema multiforme, toxic skin eruption, dermatitis exfoliative, dermatitis bullous</p><p>Photosensitivity reactions</p><p>Alopecia</p><p>If progressive skin rash occurs, Lamifen treatment should be discontinued.</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Psoriasiform eruptions or exacerbation of psoriasis. Serious skin reactions (e.g. acute generalized exanthematous pustulosis (AGEP))</p><p>Drug rash with eosinophilia and systemic symptoms</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Very common</p></td><td style="vertical-align:top; width:61.0%"><p>Musculoskeletal reactions (arthralgia, myalgia).</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Rhabdomyolysis</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>General disorders</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Rare</p></td><td style="vertical-align:top; width:61.0%"><p>Malaise</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Fatigue</p><p>Influenza-like illness, pyrexia</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p><strong>Investigations</strong></p></td><td style="vertical-align:top; width:61.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Uncommon</p></td><td style="vertical-align:top; width:61.0%"><p>Weight decreased**</p><p>**weight decreased secondary to dysgeusia</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:39.0%"><p>Not known</p></td><td style="vertical-align:top; width:61.0%"><p>Blood creatine phosphokinase increased</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />&bull; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A few cases of overdose (up to 5g) have been reported, giving rise to headache, nausea, upper abdominal pain and dizziness. The recommended treatment of overdosage consists of eliminating the drug, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if needed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Oral antifungal agent (ATC code D01B A02) Terbinafine is an allylamine which has a broad spectrum of antifungal activity. At low concentrations terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi. The activity versus yeasts is fungicidal or fungistatic depending on the species. Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death. Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane. The enzyme squalene epoxidase is not linked to the cytochrome P450 system. When given orally, the drug concentrates in skin at levels associated with fungicidal activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in">Following oral administration, terbinafine is well absorbed (&gt;70%) and the absolute bioavailability of terbinafine from Lamifen tablets as a result of first-pass metabolism is approximately 50%. A single oral dose of 250mg terbinafine resulted in mean peak plasma concentrations of 1.30&mu;g/ml within 1.5 hours after administration. Plasma concentrations decline in a triphasic manor, with a terminal half-life of 16.5 days. At 28 days, when around 70% steady state levels have been achieved, peak concentrations of terbinafine was on average 25% higher and plasma AUC increased by a factor of 2.3 when compared to single dose administration. From the increase in plasma AUC an effective half-life of ~30 hours can be calculated. The bioavailability of terbinafine is moderately affected by food (increase in the AUC of less than 20%), but not sufficiently to require dose adjustments.</p><p style="margin-left:0in; margin-right:0in; text-align:start">Terbinafine binds strongly to plasma proteins. It rapidly diffuses through the dermis and concentrates in the lipophilic stratum corneum. Terbinafine is also secreted in sebum, thus achieving high concentrations in hair follicles, hair and sebum rich skins. There is also evidence that terbinafine is distributed into the nail plate within the first few weeks of commencing therapy.</p><p style="margin-left:0in; margin-right:0in; text-align:start">Terbinafine is metabolised rapidly and extensively by at least seven CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19. Biotransformation results in metabolites with no antifungal activity, which are excreted predominantly in the urine.</p><p style="margin-left:0in; margin-right:0in; text-align:start">No clinically-relevant age-dependent changes in pharmacokinetics have been observed but the elimination rate may be reduced in patients with renal or hepatic impairment, resulting in higher blood levels of terbinafine.</p><p style="margin-left:0in; margin-right:0in; text-align:start">Single dose pharmacokinetic studies in patients with renal impairment (creatinine clearance &lt;50 ml/min) or with pre-existing liver disease have shown that clearance of Lamifen may be reduced by about 50%.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In long-term studies (up to 1 year) in rats and dogs no marked toxic effects were seen in either species up to oral doses of about 100mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 156 (females) mg/kg a day. In a two-year oral carcinogenicity study in rats, an increased incidence of liver tumours was observed in males at the highest dosage level of 69mg/kg a day. The changes which may be associated with peroxisome proliferation have been shown to be species-specific since they were not seen in the carcinogenicity study in mice, dogs or monkeys.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">During high-dose studies in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level 50mg/kg). These irregularities were associated with the presence of a terbinafine metabolite in ocular tissue and disappeared after drug discontinuation. They were not associated with histological changes.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">A standard battery of&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;genotoxicity tests revealed no evidence of mutagenic or clastogenic potential.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">No adverse effects on fertility or other reproduction parameters were observed in studies in rats or rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize Starch, Microcrystalline Cellulose, Sodium Starch Glycolate, Hydroxy Propyl Methyl Cellulose, Aerosil (Silicon Dioxide Colloidal), Magnesium Stearate &amp; Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum, PVC-PVDC blister pack containing 7 or 14 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Plot No. ME 1:3, Phase V, Industrial City, Jeddah Postal address: P.O. Box 6267 Jeddah 21442, Saudi Arabia. Tel: 00966-12-6081111 Fax: 00966-12-6081222 E-mail: jpharma@jamjoompharma.com Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>